Cipamfylline

Structural formula
General
Non-proprietary name	Cipamfylline
other names	8-Amino-1,3-bis (cyclopropylmethyl) purine-2,6-dione ( IUPAC ) BRL 61063
Molecular formula	C 13 H 17 N 5 O 2
External identifiers / databases
CAS number 132210-43-6 EC number 603-557-3 ECHA InfoCard 100.124.132 PubChem 71356 ChemSpider 64456 Wikidata Q1092675
properties
Molar mass	275.31 g · mol -1
safety instructions
GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Cipamfylline is a type 4 phosphodiesterase inhibitor . As a dermatological agent, it should be used against atopic eczema .

History

Cipamfylline was synthesized in the late 1980s by the Gronau company Beecham-Wülfing (today GlaxoSmithKline ). Cipamfylline has been clinically tested since the late 1990s. In 2002, the manufacturer stopped development because the plasma levels could not be sufficiently high .

Individual evidence

1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
2. ↑ Harald Maschler et al. (March 23, 1989): Great Britain Patent Application No. 8906792.0 .
3. ↑ CEM Griffiths, EJM van Leent, M. Gilbert, J. Traulsen (2002): Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis . In: British Journal of Dermatology , 147 (2): 299-307. doi : 10.1046 / j.1365-2133.2002.04894.x

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !